Market Cap | 499.41M | P/E | - | EPS this Y | -4.40% | Ern Qtrly Grth | - |
Income | -57.86M | Forward P/E | -8.32 | EPS next Y | 3.00% | 50D Avg Chg | 3.00% |
Sales | 76.58M | PEG | -0.25 | EPS past 5Y | - | 200D Avg Chg | 25.00% |
Dividend | N/A | Price/Book | 3.74 | EPS next 5Y | 20.10% | 52W High Chg | -46.00% |
Recommedations | 1.80 | Quick Ratio | 7.75 | Shares Outstanding | 39.15M | 52W Low Chg | 225.00% |
Insider Own | 5.21% | ROA | -20.25% | Shares Float | 37.46M | Beta | 0.63 |
Inst Own | 94.11% | ROE | -49.22% | Shares Shorted/Prior | 1.80M/1.45M | Price | 13.23 |
Gross Margin | 74.19% | Profit Margin | -75.56% | Avg. Volume | 239,400 | Target Price | 14.00 |
Oper. Margin | -75.17% | Earnings Date | Oct 28 | Volume | 203,025 | Change | -4.20% |
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Piper Sandler | Overweight | Aug 1, 24 |
Canaccord Genuity | Buy | Aug 1, 24 |
Wells Fargo | Equal-Weight | Aug 1, 24 |
Lake Street | Buy | Jun 4, 24 |
Canaccord Genuity | Buy | May 2, 24 |
Piper Sandler | Overweight | Apr 3, 24 |
Citigroup | Buy | Feb 23, 24 |
Wells Fargo | Equal-Weight | Feb 23, 24 |
Stifel | Buy | Feb 22, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Rose Geoffrey Beran | CHIEF COMMERCIAL OFF.. CHIEF COMMERCIAL OFFICER | Jan 22 | Sell | 13.13 | 1,184 | 15,546 | 244,233 | 01/24/24 |
French Glendon E. III | PRESIDENT AND CEO PRESIDENT AND CEO | Jan 18 | Sell | 12.77 | 10,000 | 127,700 | 1,141,344 | 01/22/24 |
French Glendon E. III | President and CEO President and CEO | Dec 21 | Sell | 12.42 | 10,000 | 124,200 | 1,151,344 | 12/22/23 |
Rose Geoffrey Beran | Chief Commercial Off.. Chief Commercial Officer | Nov 22 | Sell | 10.60 | 1,184 | 12,550 | 249,469 | 11/27/23 |
Rose Geoffrey Beran | Chief Commercial Off.. Chief Commercial Officer | Oct 23 | Sell | 8.35 | 1,184 | 9,886 | 250,653 | 10/25/23 |
Rose Geoffrey Beran | Chief Commercial Off.. Chief Commercial Officer | Sep 22 | Sell | 10.51 | 1,184 | 12,444 | 251,837 | 09/26/23 |
Sung Derrick | Chief Financial Offi.. Chief Financial Officer | Sep 01 | Sell | 10.01 | 4,219 | 42,232 | 391,041 | 09/06/23 |
Rose Geoffrey Beran | Chief Commercial Off.. Chief Commercial Officer | Sep 01 | Sell | 10.01 | 2,843 | 28,458 | 253,021 | 09/06/23 |
Rose Geoffrey Beran | Chief Commercial Off.. Chief Commercial Officer | Aug 23 | Sell | 10.54 | 1,184 | 12,479 | 255,864 | 08/25/23 |
French Glendon E. III | President and CEO President and CEO | Jul 20 | Sell | 12.68 | 15,000 | 190,200 | 1,174,547 | 07/24/23 |
Sung Derrick | Chief Financial Offi.. Chief Financial Officer | Jun 01 | Sell | 11.49 | 4,222 | 48,511 | 395,260 | 06/02/23 |
Rose Geoffrey Beran | Chief Commercial Off.. Chief Commercial Officer | Jun 01 | Sell | 11.48 | 2,845 | 32,661 | 257,048 | 06/02/23 |
Lehman David Aaron | General Counsel General Counsel | Jun 01 | Sell | 11.48 | 3,776 | 43,348 | 157,420 | 06/02/23 |
French Glendon E. III | President and CEO President and CEO | Jun 01 | Sell | 11.48 | 6,533 | 74,999 | 1,199,547 | 06/02/23 |
French Glendon E. III | President and CEO President and CEO | Mar 01 | Sell | 11.03 | 2,895 | 31,932 | 1,032,580 | 03/03/23 |
French Glendon E. III | President and CEO President and CEO | Dec 01 | Sell | 5.93 | 3,631 | 21,532 | 1,034,313 | 12/05/22 |
Lehman David Aaron | General Counsel General Counsel | Dec 01 | Sell | 5.93 | 1,069 | 6,339 | 44,160 | 12/05/22 |
Rose Geoffrey Beran | Chief Commercial Off.. Chief Commercial Officer | Dec 01 | Sell | 5.93 | 1,055 | 6,256 | 181,037 | 12/05/22 |
Sung Derrick | Chief Financial Offi.. Chief Financial Officer | Dec 01 | Sell | 5.93 | 1,069 | 6,339 | 262,746 | 12/05/22 |
Lynch Alissa Hsu | Director Director | Nov 29 | Buy | 5.51 | 1,700 | 9,367 | 11,910 | 12/01/22 |
Ferrari Richard | Director Director | Nov 08 | Buy | 5.3 | 5,438 | 28,821 | 30,035 | 11/10/22 |
Sung Derrick | Chief Financial Offi.. Chief Financial Officer | Sep 01 | Sell | 17.87 | 1,082 | 19,335 | 253,815 | 09/06/22 |
Rose Geoffrey Beran | Chief Commercial Off.. Chief Commercial Officer | Sep 01 | Sell | 17.89 | 1,027 | 18,373 | 182,092 | 09/06/22 |
Lehman David Aaron | General Counsel General Counsel | Sep 01 | Sell | 17.89 | 1,082 | 19,357 | 45,229 | 09/06/22 |
French Glendon E. III | President and CEO President and CEO | Sep 01 | Sell | 17.87 | 2,940 | 52,538 | 1,052,944 | 09/06/22 |
French Glendon E. III | President and CEO President and CEO | Aug 18 | Sell | 20.59 | 50,000 | 1,029,500 | 1,055,884 | 08/22/22 |
Rose Geoffrey Beran | Chief Commercial Off.. Chief Commercial Officer | Jun 01 | Sell | 18.05 | 1,011 | 18,249 | 183,118 | 06/03/22 |
Sung Derrick | Chief Financial Offi.. Chief Financial Officer | Jun 01 | Sell | 18.05 | 1,065 | 19,223 | 254,897 | 06/03/22 |
French Glendon E. III | President and CEO President and CEO | Jun 01 | Sell | 18.05 | 2,523 | 45,540 | 1,104,994 | 06/03/22 |
Lehman David Aaron | General Counsel General Counsel | Jun 01 | Sell | 18.05 | 1,065 | 19,223 | 46,311 | 06/03/22 |
Rose Geoffrey Beran | Chief Commercial Off.. Chief Commercial Officer | Mar 10 | Option | 2.10 | 29,427 | 61,797 | 184,129 | 03/11/22 |
Sung Derrick | Chief Financial Offi.. Chief Financial Officer | Mar 01 | Sell | 25.91 | 458 | 11,867 | 224,962 | 03/03/22 |
Rose Geoffrey Beran | Chief Commercial Off.. Chief Commercial Officer | Mar 01 | Sell | 25.91 | 426 | 11,038 | 123,702 | 03/03/22 |
Lehman David Aaron | General Counsel General Counsel | Mar 01 | Sell | 25.91 | 458 | 11,867 | 16,376 | 03/03/22 |
French Glendon E. III | President and CEO President and CEO | Mar 01 | Sell | 25.91 | 1,132 | 29,330 | 1,062,817 | 03/03/22 |
French Glendon E. III | President and CEO President and CEO | Feb 17 | Sell | 27.05 | 25,000 | 676,250 | 1,063,949 | 02/22/22 |
French Glendon E. III | President and CEO President and CEO | Jan 20 | Sell | 24.91 | 25,000 | 622,750 | 1,088,949 | 01/24/22 |
French Glendon E. III | President and CEO President and CEO | Dec 16 | Sell | 31.33 | 25,000 | 783,250 | 1,113,949 | 12/17/21 |
Sung Derrick | Chief Financial Offi.. Chief Financial Officer | Dec 14 | Sell | 31.66 | 6,000 | 189,960 | 225,420 | 12/16/21 |
French Glendon E. III | President and CEO President and CEO | May 20 | Option | 2.2 | 10,000 | 22,000 | 1,259,884 | 12/03/21 |
French Glendon E. III | President and CEO President and CEO | May 20 | Sell | 41.6 | 25,000 | 1,040,000 | 1,234,884 | 12/03/21 |
French Glendon E. III | President and CEO President and CEO | Apr 15 | Option | 2.2 | 25,000 | 55,000 | 1,274,884 | 12/03/21 |
French Glendon E. III | President and CEO President and CEO | Apr 15 | Sell | 43.93 | 25,000 | 1,098,250 | 1,249,884 | 12/03/21 |
French Glendon E. III | President and CEO President and CEO | Nov 18 | Sell | 36.51 | 25,000 | 912,750 | 1,105,370 | 11/22/21 |
French Glendon E. III | President and CEO President and CEO | Oct 21 | Sell | 39.81 | 25,000 | 995,250 | 1,130,370 | 10/22/21 |